冠状动脉疾病
内科学
医学
接收机工作特性
心脏病学
置信区间
曲线下面积
冠状动脉造影
冠状动脉
动脉
计算机辅助设计
生物
心肌梗塞
生物化学
作者
Stéphane Jaisson,Mohsen Kerkeni,Izabella Castilhos Ribeiro dos Santos-Weiss,Faouzi Addad,Mohammed Hammami,Philippe Gillery
标识
DOI:10.1515/cclm-2014-0642
摘要
Abstract Carbamylation is a non-enzymatic post-translational modification of proteins that has been recently identified as a non-traditional risk factor for atherosclerosis. The aim of this study was to determine whether serum homocitrulline (HCit), a characteristic carbamylation-derived product, was related to the presence and the severity of coronary artery disease (CAD). Forty-five control subjects and 109 patients were included in this cross-sectional study. After coronary angiography, the patients were classified as non-CAD patients (patients with normal arteries, n=33) and CAD patients (n=76). The severity of CAD was then evaluated using the Gensini scoring system. Serum total HCit concentrations were determined by LC-MS/MS. Serum HCit concentrations were significantly (p<0.001) higher in CAD patients than in control or non-CAD subjects. The receiver operating characteristic curve analysis showed an area under the curve equal to 0.908 (95% confidence interval, 0.853–0.964, p<0.001) and a threshold HCit concentration of 0.16 mmol/mol Lys for predicting the presence of CAD (78.9% sensitivity and 78.8% specificity). HCit concentrations significantly (p<0.001) increased concomitantly with the severity of CAD and were positively correlated with Gensini scores (r=0.725, p<0.001) as well as with the number of stenotic coronary arteries (p<0.001). Furthermore, in a multiple stepwise regression analysis, HCit was significantly (p<0.001) and independently associated with the presence of CAD, the Gensini score, and the number of stenotic arteries (standardized β values of 0.525, 0.722, and 0.642, respectively). Our results demonstrate that serum HCit concentrations are increased during CAD and are positively associated with the severity of the disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI